multiple myeloma
Gilead has high hopes that anito-cel, a multiple myeloma cell therapy it is developing with Arcellx, can bolster its cell therapy franchise.
Aurigene Oncology Advancing BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma Trial
After seeing a 100 percent response rate in Phase I, Indian health authorities said the firm can test ribrecabtagene autoleucel in Phase II of the SWASTH trial.
BMS, 2seventy End Phase III Trial of Maintenance Abecma in Multiple Myeloma Due to Low Enrollment
The firms said the trial had enrolled only 10 percent of the target study population after one year.
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
BostonGene, Mount Sinai Partner on Multiple Myeloma Precision Oncology Study
The study will use BostonGene's assays, including whole-exome and whole-transcriptome sequencing, to inform patients' clinical care and advance drug development.